/
AUTL
$1.65+$0.04 (+2.48%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$428.5M
266M shares
52-week range
$1.18 – $2.70
31% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
ADRC
Borrow rate
2.33%
Moderate
Price (6 mo)
Loading chart…
Change$-4.99
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $2.9M | $1.7M | $1.5M | $6.2M | $1.7M | $10.1M | $75.6M |
| Cost of revenue | $48.3M | $105.4M | $134.9M | $0 | $0 | $0 | $141.0M | $96.6M |
| Gross profit | −$47.3M | −$102.5M | −$133.2M | $1.5M | $6.2M | $1.7M | −$130.9M | −$21.0M |
| Gross margin | -4520.4% | -3525.1% | -7765.2% | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| R&D | $24.6M | $105.6M | $135.0M | $110.8M | $117.4M | $130.5M | $158.1M | $128.6M |
| Operating income | −$57.5M | −$247.6M | −$303.1M | −$140.4M | −$142.9M | −$179.7M | −$241.4M | −$281.4M |
| EBITDA | −$50.3M | −$137.4M | −$162.6M | −$132.5M | −$132.2M | −$156.8M | −$233.1M | −$250.3M |
| Net income | −$31.1M | −$123.8M | −$142.1M | −$142.1M | −$148.8M | −$208.4M | −$220.7M | −$288.2M |
| Net margin | -2976.5% | -4258.9% | -8285.4% | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (diluted) | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.87 | -1.08 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $129M | $-0.87 | $-0.98–$-0.70 | 7 |
| 2027 | $199M | $-0.61 | $-0.75–$-0.37 | 7 |
| 2028 | $292M | $-0.46 | $-0.72–$-0.16 | 6 |
| 2029 | $463M | $-0.12 | $-0.14–$-0.10 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
www.autolus.com- Employees
- 752
- IPO / List date
- Jun 22, 2018
- HQ
- LONDON, X0
Held by traders on TradeandTell
No one on the platform currently holds AUTL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,299,499 | $3.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AUTL yet.
